Blogs

Curated collection of publications from JITC  

JITC is committed to disseminating the most current COVID-19 and other coronavirus-related information and research to the oncology community and public at a rapid pace. Articles in this collection will be updated on a regular basis as they reach publication in the journal. To search for other content of interest within the journal, visit jitc.bmj.com.

• Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination (24 April 2024)
• Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile (31 January 2024)
• mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer (4 January 2024)
• Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment (19 February 2023)
• COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis (6 February 2023)
• SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report (27 January 2023)
• Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries (30 November 2022)
• T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine (17 July 2022)
• Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies (22 June 2022)
• Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study (9 March 2022)
• Spontaneous tumor regression following COVID-19 vaccination (3 March 2022)
• Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis (29 Nov 2021)
• Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations (30 April 2021)
• Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score (22 March 2021)
• SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study (16 Feb 2021)
• COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report (11 Feb 2021)
• Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (19 Jan 2021)
• Management of immune checkpoint therapy for patients with cancer in the face of COVID-19 (10 Dec 2020)
• Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management (20 Nov 2020)
• Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey (16 Oct 2020)
• Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (15 Oct 2020)
• A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study (6 Sept 2020)
• Outcomes and biomarker analyses among COVID-19 patients treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy (11 Aug 2020)
• SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity (29 July 2020)
• Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment (21 July 2020)
• ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-COV-2 COVID-19 (16 July 2020)
• BCG vaccine and COVID-19: Implications for infection prophylaxis and cancerimmunotherapy (6 July 2020)
• On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 (1 July 2020)
• Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management (18 June 2020)
• Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy (19 May 2020)
• COVID-19 and lung cancer: risks, mechanisms and treatment interactions (19 May 2020)
• COVID-19 and immune checkpoint inhibitors: initial considerations (19 May 2020)
• The Society for Immunotherapy of Cancer perspective on regulation of interleukin 6 signaling in COVID-19-related systemic inflammatory response (7 May 2020)
• Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19 (16 April 2020)

Please continue to check back for updated content. For additional COVID-19 resources and discussion forums, visit SITC’s COVID-19 Resources page.

The special series from JITC, COVID-19 and Cancer Immunotherapy, edited by Paolo Antonio Ascierto, MD and Jason Goldman, MD, MPH, and authored by leading voices in the immuno-oncology, infectious disease, and virology fields, is a set of authoritative reviews that serves as a valuable resource illustrating the impact COVID-19 has on cancer patients undergoing immunotherapy, providing guidance on clinical decision-making, and offering insights on the use of immunotherapy to treat COVID-19 manifestations.

EXPLORE THE SERIES